1786 related articles for article (PubMed ID: 25012934)
1. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
4. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
6. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS;
Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
[TBL] [Abstract][Full Text] [Related]
8. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
9. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
[TBL] [Abstract][Full Text] [Related]
12. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
15. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
[TBL] [Abstract][Full Text] [Related]
16. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
18. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
[TBL] [Abstract][Full Text] [Related]
20. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
